Read + Share
Nierengarten MB. Durvalumab not cost-effective with current pricing strategies for stage III
NSCLC: The drug remains inaccessible to many patients for whom it is indicated as
a standard of care after chemoradiation. Cancer 2024;130:3236.
PMID: 39226077
|
 |
|
